Advaxis in deal with Cobra for Lovaxin
USA-based Advaxis has signed an agreement with UK firm Cobra Biomanufacturing for the production of its Phase II clinical trial material of a therapeutic cervical cancer vaccine known as Lovaxin C.
John Rothman, vice president, clinical development, at Advaxis, said: "we look forward to continuing our relationship with Cobra as we move forward with the development of live Listeria vaccines for the treatment of cancer. Our initial clinical work demonstrated the real world utility of our concepts, and Cobra's ability to execute their production as potential cancer immunotherapeutic agents."
David Thatcher, chief executive of Cobra, added: "we have been supporting the Advaxis Lovaxin C clinical program since 2003 and are delighted to extend our work with Advaxis on this exciting project."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze